Who has advanced heart failure? Definition and epidemiology

Congestive Heart Failure

Volumn 17, Issue 4, 2011, Pages 160-168

  Abouezzeddine, Omar F ^a   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN TYPE NATRIURETIC PEPTIDE; DIURETIC AGENT; INOTROPIC AGENT; PEPTIDE HORMONE; UNCLASSIFIED DRUG; URIC ACID; VASOACTIVE AGENT;

ABDOMINAL DISTENSION; ADVANCED HEART FAILURE; AGING; CACHEXIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CENTRAL SLEEP APNEA SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY DISEASE; DEATH; DEMOGRAPHY; DEPRESSION; DISEASE COURSE; DOPPLER ECHOGRAPHY; EDEMA; EVALUATION STUDY OF CONGESTIVE HEART FAILURE AND PULMONARY ARTERY CATHETERIZATION EFFECTIVENESS RISK MODEL AND DISCHARGE SCORE; FATIGUE; FLUID RETENTION; HEALTH CARE UTILIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE SURVIVAL SCORE; HEART INDEX; HEART PERFUSION; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HIGH RISK POPULATION; HISTORY; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERVOLEMIA; HYPONATREMIA; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; LEFT VENTRICULAR ASSIST DEVICE; LUNG WEDGE PRESSURE; MORTALITY; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON HEART FAILURE RELATED DEATH; OPTIMAL MEDICAL THERAPY; OUTPATIENT; OXYGEN CONSUMPTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEATTLE HEART FAILURE MODEL; SEX; SLEEP DISORDER; SUDDEN DEATH; SURVIVAL; SURVIVAL TIME; SYSTOLIC DYSFUNCTION; THERAPY; UNITED STATES;

CARDIAC RESYNCHRONIZATION THERAPY; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; HEART FAILURE; HEART-ASSIST DEVICES; HEMODYNAMICS; HOSPITALIZATION; HUMANS; PREVALENCE; PROGNOSIS; VENTRICULAR DYSFUNCTION;

EID: 79960702225     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00246.x     Document Type: Review

References (84)

1. Redfield MM. Heart failure - an epidemic of uncertain proportions. N Engl J Med. 2002;347(18):1442-1444.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
3. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344-350.
4. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-1402.
5. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30-41.
6. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: aCCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977-2016.
7. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed.: Philadelphia, PA: WB Saunders Company; 1997.
8. Dunlay SM, Shah ND, Shi Q, et al. Lifetime costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes. 2011;4(1):68-75.
9. Henkel DM, Redfield MM, Weston SA, et al. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1(2):91-97.
10. Dunlay SM, Redfield MM, Weston SA, et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009;54(18):1695-1702.
11. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16(6):e1-e194.
12. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;7:684-694.
13. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316(23):1429-1435.
14. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468-1475.
15. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107-1114.
16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
17. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717.
18. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-1658.
19. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344(12):873-880.
20. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.
21. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845-1853.
22. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289(20):2685-2694.
23. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-2150.
24. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625-1633.
25. Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail. 2008;1(1):9-16.
26. Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure - the PERSIST study. Eur J Heart Fail. 2008;10(12):1246-1254.
27. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241-2251.
28. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659-1667.
29. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44-54.
30. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-1549.
31. Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. J Am Coll Cardiol. 1999;33(3):734-742.
32. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290(19):2581-2587.
33. Costanzo MR, Mills RM, Wynne J. Characteristics of "Stage D" heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). Am Heart J. 2008;155(2):339-347.
34. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260-266.
35. Thohan V. Prognostic implications of echocardiography in advanced heart failure. Curr Opin Cardiol. 2004;19(3):238-249.
36. Hamdan A, Shapira Y, Bengal T, et al. Tissue Doppler imaging in patients with advanced heart failure: relation to functional class and prognosis. J Heart Lung Transplant. 2006;25(2):214-218.
37. Meta-analysis Research Group in Echocardiography (MeRGE) Heart Failure Collaborators. Independence of restrictive filling pattern and LV ejection fraction with mortality in heart failure: an individual patient meta-analysis. Eur J Heart Fail. 2008;10(8):786-792.
38. Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009;15(7):586-592.
39. Meluzin J, Spinarova L, Dusek L, et al. Prognostic importance of the right ventricular function assessed by Doppler tissue imaging. Eur J Echocardiogr. 2003;4(4):262-271.
40. Grayburn PA, Appleton CP, DeMaria AN, et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol. 2005;45(7):1064-1071.
41. Lee TH, Hamilton MA, Stevenson LW, et al. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol. 1993;72(9):672-676.
42. Rihal CS, Nishimura RA, Hatle LK, et al. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Circulation. 1994;90:2772-2779.
43. Deng MC, Gradaus R, Hammel D, et al. Heart transplant candidates at high risk can be identified at the time of initial evaluation. Transpl Int. 1996;9(1):38-45.
44. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569-582.
45. Douglas PS, Morrow R, Ioli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1989;13(2):311-315.
46. St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107(20):2577-2582.
47. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25(5):1143-1153.
48. Gavazzi A, Berzuini C, Campana C, et al. Value of right ventricular ejection fraction in predicting short-term prognosis of patients with severe chronic heart failure. J Heart Lung Transplant. 1997;16(7):774-785.
49. Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol. 2002;39(9):1450-1455.
50. Ghio S, Recusani F, Klersy C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 2000;85(7):837-842.
51. Karatasakis GT, Karagounis LA, Kalyvas PA, et al. Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure. Am J Cardiol. 1998;82(3):329-334.
52. Hansen A, Haass M, Zugck C, et al. Prognostic value of Doppler echocardiographic mitral inflow patterns: implications for risk stratification in patients with chronic congestive heart failure. J Am Coll Cardiol. 2001;37(4):1049-1055.
53. Yamamoto T, Oki T, Yamada H, et al. Prognostic value of the atrial systolic mitral annular motion velocity in patients with left ventricular systolic dysfunction. J Am Soc Echocardiogr. 2003;16(4):333-339.
54. Abramson SV, Burke JF, Kelly JJ Jr, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116(11):888-895.
55. Shah RV, Semigran MJ. Pulmonary hypertension secondary to left ventricular systolic dysfunction: contemporary diagnosis and management. Curr Heart Fail Rep. 2008;5(4):226-232.
56. Patel JB, Borgeson DD, Barnes ME, et al. Mitral regurgitation in patients with advanced systolic heart failure. J Card Fail. 2004;10(4):285-291.
57. Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol. 1990;66(19):1348-1354.
58. Morley D, Brozena SC. Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am J Cardiol. 1994;73(5):379-383.
59. Stevenson LW, Zile M, Bennett TD, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010;3(5):580-587.
60. Packer M, Medina N, Yushak M. Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med. 1984;100(6):782-789.
61. Taub PR, Daniels LB, Maisel AS. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart Fail clin. 2009;5(2):169-175.
62. Miller WL, Burnett JC Jr, Hartman KA, et al. Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide. Am J Cardiol. 2005;96(6):837-841.
63. Lainscak M, Anker SD. Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems. Herz. 2009;34(2):141-147.
64. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail. 2009;11(5):444-452.
65. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102(2):203-210.
66. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987-1996.
67. Dunlay SM, Weston SA, Redfield MM, et al. Anemia and heart failure: a community study. Am J Med. 2008;121(8):726-732.
68. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113(11):1424-1433.
69. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol. 2009;53(4):334-342.
70. Gorodeski EZ, Chu EC, Chow CH, et al. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. Circ Heart Fail. 2010;3(6):706-714.
71. Levy WC, Mozaffarian D, Linker DT, et al. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant. 2009;28(3):231-236.
72. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95(12):2660-2667.
73. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003;92(11):1350-1354.
74. Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. Am J Cardiol. 2005;95(6):734-741.
75. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant. 2004;23(12):1414-1422.
76. Lim E, Ali Z, Ali A, et al. Comparison of survival by allocation to medical therapy, surgery, or heart transplantation for ischemic advanced heart failure. J Heart Lung Transplant. 2005;24(8):983-989.
77. O'Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol. 2010;55(9):872-878.
78. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28(6):535-541.
79. Boyle AJ, Ascheim DD, Russo MJ, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. 2011;30(4):402-407.
80. Alba AC, Rao V, Ivanov J, et al. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant. 2009;28(8):827-833.
81. Lund LH, Matthews J, Aaronson K. Patient selection for left ventricular assist devices. Eur J Heart Fail. 2010;12(5):434-443.
82. Miller LW. Left ventricular assist devices are underutilized. Circulation. 2005;123(14):1552-1558.
83. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287(5):628-640.
84. Gheorghiade M, Cody RJ, Francis GS, et al. Current medical therapy for advanced heart failure. Heart Lung. 2000;29(1):16-32.